EUVIMEDEUVIMED entdecken
Multizentrische Studie

Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study

Rongbei Liu iD, Zhilun Li, Lingna Ye, Jing Hu, Jian Tang iD, Baili Chen, Xiuli Chen, Bei Tan, Yubei Gu, Chen Xie, Chunhui Ouyang, Xiaomei Song und 7 weitere

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad032 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Rongbei Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Hauptthemen laut MEDLINE: Crohn Disease, Hepatitis B, Latent Tuberculosis. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Zhejiang Medical and Health Science and Technology Project, Zhejiang Medical and Health Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ustekinumab (UST) was approved in China for moderate-to-severe Crohn’s disease (CD) in 2020. The prevalence rates of tuberculosis and hepatitis B virus (HBV) infection are high in China, and no guideline clearly states that tuberculosis chemoprophylaxis or prophylactic anti-HBV therapy should be prescribed before UST administration. This study aimed to assess the risk of tuberculosis and HBV reactivation in CD patients with latent tuberculosis infection (LTBI) and previous HBV infection receiving UST.

Methods

A multicenter retrospective cohort study was carried out at 68 hospitals in China to assess 721 adult CD cases administered UST between May 1, 2020, and December 31, 2021. CD and concurrent LTBI or HBV carrier were included. Hepatitis B serology, T-SPOT.TB, and tuberculin skin tests were performed at baseline. The primary outcome was tuberculosis or HBV reactivation.

Results

Patients with CD-concomitant LTBI or who were HBV carriers receiving UST therapy were retrospectively enrolled from 15 hospitals in China. A total of 53 CD with LTBI patients and 17 CD with HBV carrier patients receiving UST were included. Treatment and follow-up durations were 50 ± 20 weeks and 50 ± 15 weeks in the LTBI and HBV carrier groups, respectively. A total of 25 CD patients with LTBI underwent chemoprophylaxis and 28 did not. A total of 11 HBV carriers had antiviral prophylaxis and 6 did not. No patient experienced tuberculosis or HBV reactivation or liver dysfunction during follow-up.

Conclusions

UST was safe for treatment of CD because no patient developed tuberculosis, persistent hepatitis, or acute liver failure during therapy, whether with a prophylactic regimen or not, based on our sample size and limited follow-up time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseHepatitis BLatent TuberculosisAdultHumansUstekinumabRetrospective StudiesHepatitis B virus

Stichwörter der Autor:innen

LTBIchronic HBV infectionustekinumab

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Department of Gastroenterology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • Center of Inflammatory Bowel Disease, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Gastroenterology, First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • Department of Gastroenterology, Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangzhou, China.

ORCID-Profile: Rongbei Liu, Jian Tang

Förderung

  • Zhejiang Medical and Health Science and Technology Project
  • Zhejiang Medical and Health Science and Technology

Zitieren

APA

Liu, R., Li, Z., Ye, L., Hu, J., Tang, J., Chen, B., Chen, X., Tan, B., Gu, Y., Xie, C., Ouyang, C., Song, X., Li, F., Fan, Y., Ren, H., Zhu, L., Chen, M., Jiang, W., & Cao, Q. (2024). Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad032

Vancouver

Liu R, Li Z, Ye L, Hu J, Tang J, Chen B, et al. Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad032

BibTeX
@article{Liu2024,
  author = {Liu, Rongbei and Li, Zhilun and Ye, Lingna and Hu, Jing and Tang, Jian and Chen, Baili and Chen, Xiuli and Tan, Bei and Gu, Yubei and Xie, Chen and Ouyang, Chunhui and Song, Xiaomei and Li, Fan and Fan, Yanyun and Ren, Haixia and Zhu, Liangru and Chen, Min and Jiang, Wenyu and Cao, Qian},
  title = {Risk of Tuberculosis and Hepatitis B Reactivation in Patients With Crohn’s Disease on Ustekinumab: A Nationwide Real-World Study},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad032}
}
Kostenlos starten →